<DOC>
	<DOCNO>NCT00737620</DOCNO>
	<brief_summary>The majority bridge graft fistula polytetrafluoroethylene ( PTFE ) hemodialysis access develop stenosis venous anastomosis eventually fail . Aspirin use many year prophylactic drug therapy prevent thrombosis good clinical evidence benefit lack . Many drug use reduce intimal hyperplasia animal model . Until recently little success clinical trial anti-inflammatory , antiproliferative , antiplatelet , antithrombotic calcium channel block drug . Recently major breakthrough do GORE introduce new heparin bond PTFE graft covalent attachment . This trial plan assess compare GORE-TEXÂ® PROPATEN vascular graft versus unmodified ePTFE graft patency complication .</brief_summary>
	<brief_title>Evaluation Heparin Bonded Vascular Graft Versus Standard Graft Prosthetic Arteriovenous Access Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Fistula</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>All patient schedule creation new prosthetic access inform consent enrol trial Investigators attempt enroll male : female ratio patient representative current patient population Anticoagulation therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Renal Failure , End Stage</keyword>
	<keyword>Blood Vessel Grafting</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Surgical Arteriovenous Shunt</keyword>
</DOC>